Fusion Antibodies (LON:FAB) Trading 3% Higher

Fusion Antibodies plc (LON:FABGet Free Report)’s share price traded up 3% on Thursday . The stock traded as high as GBX 3.52 ($0.04) and last traded at GBX 3.45 ($0.04). 315,788 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,129,699 shares. The stock had previously closed at GBX 3.35 ($0.04).

Fusion Antibodies Stock Performance

The company has a debt-to-equity ratio of 3.23, a current ratio of 3.26 and a quick ratio of 2.36. The firm has a market cap of £3.29 million, a price-to-earnings ratio of -38.33 and a beta of 0.46. The company has a fifty day moving average price of GBX 3.62 and a two-hundred day moving average price of GBX 4.15.

Fusion Antibodies Company Profile

(Get Free Report)

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.

See Also

Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.